MWM
NVCT icon

Moran Wealth Management’s Nuvectis Pharma NVCT Stock Holding History

Moran Wealth Management’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16,697
Closed -$215K – 445
2023
Q3 		$215K Buy
+16,697
New +$242K 0.01% 347

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Moran Wealth Management's NVCT Position: Q4 2023 in Review

Moran Wealth Management sold out of Nuvectis Pharma (NVCT) in Q4 2023, closing a stake of 16,697 shares — an estimated $215K sold.

Moran Wealth Management first reported a position in NVCT in Q3 2023 and held it in 1 quarter. The position peaked at $215K in Q3 2023. 36 funds tracked by Wall St. Rank hold NVCT as of Q4 2023.

  • Moran Wealth Management reported no remaining Nuvectis Pharma position as of Q4 2023 after selling out during the quarter.
  • Moran Wealth Management sold 16,697 Nuvectis Pharma shares in Q4 2023, an estimated $215K.
  • Moran Wealth Management first reported a position in Nuvectis Pharma in Q3 2023 and held it in 1 quarter.
  • Moran Wealth Management's Nuvectis Pharma position peaked at $215K in Q3 2023.
  • 36 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q4 2023.

Based on Moran Wealth Management's 13F filing for Q4 2023, filed 8 Feb 2024.